PMC:7795856 / 5086-5322 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"150","span":{"begin":18,"end":26},"obj":"Disease"},{"id":"151","span":{"begin":45,"end":60},"obj":"Disease"},{"id":"161","span":{"begin":167,"end":170},"obj":"Gene"}],"attributes":[{"id":"A150","pred":"tao:has_database_id","subj":"150","obj":"MESH:C000657245"},{"id":"A151","pred":"tao:has_database_id","subj":"151","obj":"MESH:D008231"},{"id":"A161","pred":"tao:has_database_id","subj":"161","obj":"Gene:134864"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"rtality of severe COVID-19 by restoration of lymphocytopenia and reversion of exhausted T cells [23].\nHowever, there are two major drawbacks of the currently marketed Tα1, both of which are related to its peptidic nature. First, the bio"}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T14","span":{"begin":45,"end":60},"obj":"Phenotype"}],"attributes":[{"id":"A14","pred":"hp_id","subj":"T14","obj":"http://purl.obolibrary.org/obo/HP_0001888"}],"text":"rtality of severe COVID-19 by restoration of lymphocytopenia and reversion of exhausted T cells [23].\nHowever, there are two major drawbacks of the currently marketed Tα1, both of which are related to its peptidic nature. First, the bio"}

{"project":"LitCovid-sentences","denotations":[{"id":"T33","span":{"begin":102,"end":221},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"rtality of severe COVID-19 by restoration of lymphocytopenia and reversion of exhausted T cells [23].\nHowever, there are two major drawbacks of the currently marketed Tα1, both of which are related to its peptidic nature. First, the bio"}